Psychedelics and Suicidality

Psychedelics and suicidality is one of the 'psychedelics and ...' topics that we're currently making a page for. At this moment you can find all papers (in our database) on this topic below.

Research Papers Compared Measured Researchers Gaps Companies

State of Research

TBD

Quality of Conclusions

TBD

Data Points

TBD Papers studying this directly
TBD Companies working on this

Make Blossom Sustainable

Blossom is free to use and will always be.

Supporting Blossom makes this possible. When you support Blossom for €20/month, you get access to our downloadable files, influence over the direction of our 'psychedelics and ...' pages, and future projects.

Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.

Suicidality Research

Here will be a narrative, readable, summary of the research.

Papers

In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.

Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine

2021 | Ballard, E. D., Farmer, C. A., Fields, J., Zarate, C. A.

This review (2021) examines methodological innovations within clinical trials investigating ketamine as a rapid-acting treatment option for depression or suicidal ideation (SI). The authors emphasize that the fast-acting dynamic of this treatment will enable the next generation of clinical trial designs to focus more on the development of better psychometric instruments, and more reliable biomarkers for assessing the efficacy of suicidal ideation treatment.

Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review

2021 | Brietzke, E., Di Vincenzo, J. D., Gill, H., Ho, R., Lui, L. M. W., McIntyre, R. S., Ng, J., Rodrigues, N. B., Rosenblat, J. D., Siegel, A. N., Teopiz, K. M.

This review (2021) evaluates the effect of esketamine and ketamine in patients with suicidal ideation at baseline. The authors find that esketamine trials did not demonstrate antisuicidal effects, while IV ketamine appeared to rapidly decrease the short term severity of suicidal ideation and depressive symptoms in individuals with baseline suicidal ideation.

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis

2017 | Ballard, E. D., Bloch, M. H., Feder, A., Mathew, S. J., Murrough, J. W., Sanacora, G., Sos, P., Wang, G., Wilkinson, S. T., Zarate, C. A.

This systematic review (2018) and meta-analysis (n=176) examined the effects of ketamine on suicidal ideation using patient-level data from various studies that applied a single-dose intravenous administration route to treat any type of psychiatric disorder. Ketamine significantly reduced suicidal ideation for up to one week after the infusion.

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

2021 | Breslow, L., Singhal, N., Weissman, C. R., Zeifman, R. J.

This review (2021; 64 studies) investigated the literature and found no clear relationship (finding correlation both ways, and non-significant results) between non-clinical use of psychedelics and suicidality. There is preliminary evidence for acute and sustained decreases in suicidality after psychedelic therapy.

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)

2020| Canuso, C. M., Drevets, W. C., Fu, D. J., Hough, D., Ionescu, D. F., Lane, R., Lim, P., Manji, H., Sanacora, G.

This placebo-controlled, double-blind study, phase 3 study (n=226) compared esketamine (84mg, nasal, 2xp/w for 4w) with a placebo spray and found esketamine to be effective in lowering depression scores (MADRS) for those suffering from depression (MDD) and suicidal ideation (SI). Scores on a measure of SI was, however, not significantly different between the two groups.

A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting

2016| Boche, B., Burger, J., Capobianco, M., Darracq, M. A., Lovern, R., McLay, R., Ross, E.

This placebo-controlled proof-of-concept study (n=10, 7 placebo) administered sub-dissociative doses of ketamine to military personnel experiencing depression and suicidal ideation (SI), and found that the ketamine infusion resulted in significant short-term improvement in two out of the three patients who received the drug.

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer

2021| Agin-Liebes, G. I., Benville, J., Bjerre-Real, C., Bossis, A. P., Franco-Corso, S., Ghazal, L., Guss, J., Lo, S., Mennenga, S. E., Ross, E., Zeifman, R. J.

This follow-up study (n=11) of psilocybin-assisted therapy for anxiety and depression, found that it also significantly reduced suicidal ideation (SI) and loss of meaning (LoM) up to the 4.5 years follow-up.

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial

2021| Domany, Y., McCullumsmith, C. B.

This double-blind placebo-controlled study study (n=30) with intranasal ketamine (40mg) found significant reductions in suicidal ideation (SI, 80 vs 33% remission) and depressive symptoms (MADRS) 4 hours after administration for those with SI in the emergency department.

Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study

2021| Beaudequin, D. A., Can, A. T., Dutton, M., Gallay, C. C., Hermens, D. F., Jensen, E., Jones, M., Lagopoulos, J., Scherman, J., Schwenn, P. E., Yang, C.

This open-label study (n=32) with 6 dosages (weekly) of oral ketamine (35-210mg/70kg) found that it significantly reduced suicidal ideation in those with chronic suicidal thought, with clinically significant lower scores in 69% of participants at the end (which held at 50% 4 weeks later).

Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

2012| Brutsche, N. E., Cravchik, A., Diazgranados, N., Franco-Chaves, J., Ibrahim, L., Liberty, V., Luckenbaugh, D. A., Marquardt, C. A., Selter, J., Zarate, C. A.

This double-blind, randomized, crossover, placebo-controlled replication study (n=15) investigated the effects of ketamine (35mg) on patients with treatment-resistant bipolar depression, and found rapid improvements of depressive symptoms, suicidal ideation, and subjective well-being within 40 minutes after infusion and up to 3 days after.

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

2018| Burke, A. K., Choo, T-H., Galfalvy, H. C., Grunebaum, M. F., Keilp, J. G., Mann, J. J., Marver, J. E., Milak, M. S., Moitra, V. K., Oquendo, M. A., Parris, M. S., Sublette, M. E.

This randomized study (n=80) found that participants with depression (MDD) and suicidal ideation (SSI/SI) who were treated with ketamine (IV, 35mg/70kg) have significantly lower SSI scores versus treatment with midazolam (another anesthetic). This effect consistently held up to 6 weeks later.

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

2020| de Lima Osório, F., Dos Santos, R. G., Hallak, J. E., Sanches, R. F., Weissman, C. R., Zeifman, R. J.

This analysis of an earlier open-label study (n=15) on Ayahuasca, found significant (Hedges' g = 1.75) and sustained decreases in suicidality in people with depression (MDD).

Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation

2020| Carhart-Harris, R. L., Kettner, H., Mertens, L. J., Wagner, A. C., Watts, R., Zeifman, R. J.

A prospective survey study (n=358) found that psychedelics may lead to significant decreases in experiential avoidance, depression severity, and suicidal ideation.

Compared

This section compares the research with psychedelics to other therapies, medicines, or treatments.

Measured

This section highlights the various measures used and their use in research.

Researchers

Who are the top researches in this area, the ones who have done the groundbreaking research.

Gaps

What do we not know at this time? Where are the gaps in our knowledge and are we closing it?

Companies

The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.

Outside Academia

This section highlights everything done outside of academia, from popular press to books and non academic research.